Results 231 to 240 of about 87,778 (377)

Dissecting stress-activated protein kinase (SAPK)-signaling pathways using multiplex gene knockout HeLa cells. [PDF]

open access: yesJ Biol Chem
Ito C   +9 more
europepmc   +1 more source

Cyclic‐AMP‐dependent protein kinase A regulates apoptosis by stabilizing the BH3‐only protein Bim

open access: yesEMBO Reports, 2011
Diane Moujalled   +9 more
semanticscholar   +1 more source

From Yeast to Therapeutics: Modeling Neurodegenerative Diseases in Saccharomyces cerevisiae

open access: yesYeast, EarlyView.
Yeast plasmids expressing human Aβ‐42, α‐syn, htt, and TDP‐43. Their fate includes an equilibrium between the endocytic pathway and aggregates that potentially disrupt endocytosis, vesicular transport, vacuolar autophagy, and mitochondrial activity. ABSTRACT Here, we review the use of Saccharomyces cerevisiae as a powerful model organism for studying ...
Jose Ribamar Ferreira‐Junior   +2 more
wiley   +1 more source

Role of 3':5'-cyclic-AMP-dependent protein kinase in regulation of protein synthesis in reticulocyte lysates.

open access: yesProceedings of the National Academy of Sciences of the United States of America, 1977
A. Datta   +3 more
semanticscholar   +1 more source

Luteinizing hormone receptor knockout mouse: What has it taught us?

open access: yesAndrology, EarlyView.
Abstract Luteinizing hormone (LH), along with its agonist choriongonadotropin (hCG) in humans, is the key hormone responsible for the tropic regulation of the gonadal function. LH and hCG act through their cognate receptor, the luteinizing hormone/choriongonadotropin receptor (LHCGR; more appropriately LHR in rodents lacking CG), located in the testis ...
Ilpo T. Huhtaniemi
wiley   +1 more source

ATP Metabolism of Astrocytes: Consumption, Regeneration and Restoration. [PDF]

open access: yesNeurochem Res
Dringen R   +3 more
europepmc   +1 more source

A structural gene mutation affecting the regulatory subunit of cyclic AMP-dependent protein kinase in mouse lymphoma cells.

open access: yesProceedings of the National Academy of Sciences of the United States of America, 1975
J. Hochman   +4 more
semanticscholar   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy